Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ERYTECH Pharma S.A.
  6. News
  7. Summary
    ERYP   FR0011471135

ERYTECH PHARMA S.A.

(ERYP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ERYTECH Pharma S A : to Participate in the HealthTech Innovation Days (HTID) by France Biotech

09/28/2021 | 04:05pm EST

ERYTECH to Participate in the HealthTech Innovation Days (HTID) by France Biotech

Cambridge, MA (U.S.) and Lyon (France), September 28, 2021 ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the company’s participation in one-on-one investor meetings at the HealthTech Innovation Days (HTID) by France Biotech being held in Paris and virtually on October 4th & 5th, 2021.

1x1 Meetings October 4th & 5th
Gil Beyen, Chief Executive Officer and Eric Soyer, Chief Financial Officer will participate in virtual one-on-one meetings on October 4th & 5th, 2021.

For more information about the HealthTech Innovation Days, please visit https://htfc-eu.com/htid/

About ERYTECH and eryaspase

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells’ altered asparagine and glutamine metabolism. Eryaspase is in a Phase 3 clinical development for the treatment of second-line pancreatic cancer, which is fully enrolled and expected to read out top-line results in Q4 2021, and in an ongoing Phase 2 for the treatment of triple-negative breast cancer. An investigator sponsored Phase 2 trial (IST) in acute lymphoblastic leukemia recently reported positive results, and a Phase 1 IST in 1L advanced pancreatic cancer is ongoing.

Eryaspase received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of advanced pancreatic cancer and treatment of acute lymphoblastic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase). The FDA and the European Medicines Agency have granted eryaspase orphan
drug status for the treatment of pancreatic cancer and ALL. ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France,
and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA. Eryaspase is not an approved medicine.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
For more information, please visit www.erytech.com
        

CONTACTS 

ERYTECH                     

Eric Soyer

CFO & COO
LifeSci Advisors, LLC

Corey Davis, Ph.D.

Investor relations

NewCap

Mathilde Bohin / Louis-Victor Delouvrier

Investor relations

Nicolas Merigeau

Media relations


+33 4 78 74 44 38

investors@erytech.com


+1 (212) 915 2577

cdavis@lifesciadvisors.com


+33 1 44 71 94 94

erytech@newcap.eu

Attachment

  • Erytech_PR_HTID Conference_EN

© OMX, source GlobeNewswire - EU Press Releases

All news about ERYTECH PHARMA S.A.
11/30European ADRs Move Lower in Tuesday Trading
MT
11/30ERYTECH PHARMA S A : Secures US Patent Directed to Sequential Use of Methioninase & Aspara..
PU
11/29Erytech Pharma Gets US Patent For Methioninase, Asparaginase in Solid Tumor Treatment
MT
11/29Erytech Pharma Secures US Patent in Methioninase, Asparaginase Use for Solid Tumors -- ..
MT
11/29ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase aga..
AQ
11/17European ADRs Higher Wednesday as Credit Suisse, Barrick Gold Gain
MT
11/16European ADRs Mixed in Tuesday Morning Trading
MT
11/15ERYTECH Provides Business and Financial Update for the Third Quarter of 2021
AQ
11/15European ADRs Move Slightly Higher in Monday Trading
MT
11/15ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematolo..
GL
More news
Analyst Recommendations on ERYTECH PHARMA S.A.
More recommendations
Financials
Sales 2021 6,74 M 7,63 M 7,63 M
Net income 2021 -61,2 M -69,4 M -69,4 M
Net Debt 2021 16,1 M 18,2 M 18,2 M
P/E ratio 2021 -0,79x
Yield 2021 -
Capitalization 68,7 M 77,4 M 77,9 M
EV / Sales 2021 12,6x
EV / Sales 2022 7,08x
Nbr of Employees 196
Free-Float 67,5%
Chart ERYTECH PHARMA S.A.
Duration : Period :
ERYTECH Pharma S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ERYTECH PHARMA S.A.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Last Close Price 2,46 €
Average target price 4,30 €
Spread / Average Target 74,8%
EPS Revisions
Managers and Directors
Gil Beyen Chief Executive Officer & Director
Eric Soyer Chief Operating & Financial Officer
Jean-Paul Kress Chairman
Iman El-Hariry Chief Medical Officer
Stewart Craig Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
ERYTECH PHARMA S.A.-65.40%77
GILEAD SCIENCES, INC.18.31%86 465
BIONTECH SE331.48%84 953
WUXI APPTEC CO., LTD.28.27%66 734
REGENERON PHARMACEUTICALS31.76%66 553
VERTEX PHARMACEUTICALS-20.90%47 530